Vistagen Therapeutics Inc (VTGN) concluded trading on Wednesday at a closing price of $2.06, with 0.41 million shares of worth about $0.85 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.23% during that period and on June 18, 2025 the price saw a loss of about -13.45%. Currently the company’s common shares owned by public are about 28.32M shares, out of which, 26.11M shares are available for trading.
Stock saw a price change of -12.71% in past 5 days and over the past one month there was a price change of -19.06%. Year-to-date (YTD), VTGN shares are showing a performance of -30.17% which decreased to -41.48% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.90 but also hit the highest price of $4.21 during that period. The average intraday trading volume for Vistagen Therapeutics Inc shares is 135.64K. The stock is currently trading -13.64% below its 20-day simple moving average (SMA20), while that difference is down -10.57% for SMA50 and it goes to -24.11% lower than SMA200.
Vistagen Therapeutics Inc (NASDAQ: VTGN) currently have 28.32M outstanding shares and institutions hold larger chunk of about 46.46% of that.
The stock has a current market capitalization of $60.06M and its 3Y-monthly beta is at 0.69. It has posted earnings per share of -$1.58 in the same period. It has Quick Ratio of 9.35 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VTGN, volatility over the week remained 8.94% while standing at 4.46% over the month.
Stock’s fiscal year EPS is expected to rise by 8.08% while it is estimated to decrease by -10.10% in next year. EPS is likely to shrink at an annualized rate of 29.31% for next 5-years, compared to annual growth of 35.63% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on December 07, 2023 offering a Buy rating for the stock and assigned a target price of $15 to it. Coverage by Maxim Group stated Vistagen Therapeutics Inc (VTGN) stock as a Buy in their note to investors on August 07, 2023, suggesting a price target of $30 for the stock. Stock get a Hold rating from Jefferies on July 22, 2022.
